MA52738A - Méthodes de traitement de l'arthrite psoriasique - Google Patents

Méthodes de traitement de l'arthrite psoriasique

Info

Publication number
MA52738A
MA52738A MA052738A MA52738A MA52738A MA 52738 A MA52738 A MA 52738A MA 052738 A MA052738 A MA 052738A MA 52738 A MA52738 A MA 52738A MA 52738 A MA52738 A MA 52738A
Authority
MA
Morocco
Prior art keywords
treatment methods
arthritis treatment
psoriasic arthritis
psoriasic
methods
Prior art date
Application number
MA052738A
Other languages
English (en)
Inventor
Pille Harrison
Luc Meuleners
Chantal Thérèse Tasset
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of MA52738A publication Critical patent/MA52738A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA052738A 2018-05-24 2019-05-23 Méthodes de traitement de l'arthrite psoriasique MA52738A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1808575.3A GB201808575D0 (en) 2018-05-24 2018-05-24 Methods for the treatment of psoriatic arthrits

Publications (1)

Publication Number Publication Date
MA52738A true MA52738A (fr) 2021-04-14

Family

ID=62812304

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052738A MA52738A (fr) 2018-05-24 2019-05-23 Méthodes de traitement de l'arthrite psoriasique

Country Status (10)

Country Link
US (1) US12329758B2 (fr)
EP (1) EP3801548A1 (fr)
JP (3) JP2021524472A (fr)
KR (1) KR20210013168A (fr)
CN (1) CN112203660B (fr)
AU (2) AU2019273664B2 (fr)
CA (1) CA3101386A1 (fr)
GB (1) GB201808575D0 (fr)
MA (1) MA52738A (fr)
WO (1) WO2019224283A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US20220025035A1 (en) * 2020-07-13 2022-01-27 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
WO2022164280A1 (fr) 2021-01-29 2022-08-04 주식회사 엘지화학 Électrode

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156037B1 (fr) 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Promoteurs de la chondrogenese et derives d'indolin-2-one
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JPWO2004039816A1 (ja) 2002-10-29 2006-03-02 塩野義製薬株式会社 セフェム化合物の無機酸塩の結晶
ES2264795T3 (es) 2003-02-14 2007-01-16 Pfizer Products Inc. Triazolo-piridinas como compuestos antiinflamatorios.
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
CA2577478A1 (fr) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Nouveaux compose de triazolopyridine
US7524860B2 (en) 2004-10-07 2009-04-28 Pfizer Inc. Antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
SG174086A1 (en) 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
CA2689514C (fr) 2007-06-05 2015-09-29 Takeda Pharmaceutical Company Limited Composes heterobicycliques comme inhibiteurs de kinase
KR20100049073A (ko) 2007-07-18 2010-05-11 노파르티스 아게 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
WO2009017954A1 (fr) 2007-08-01 2009-02-05 Phenomix Corporation Inhibiteurs de kinase jak2
JP2010536917A (ja) 2007-08-31 2010-12-02 メルク セローノ ソシエテ アノニム トリアゾロピリジン化合物と、ａｓｋ阻害剤としてのその化合物の利用法
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2009259867A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010189A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010184A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4]triazolo[1, 5-a]pyridines utilisées comme inhibiteurs de jak
WO2010010188A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010187A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010186A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
US20110124692A1 (en) 2008-07-31 2011-05-26 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione compound and its manufacturing method
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JP2013049632A (ja) 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
MY177334A (en) * 2012-06-22 2020-09-12 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
SG11201708198SA (en) 2015-04-13 2017-11-29 Galapagos Nv Methods for the treatment of cardiovascular disorders
KR20170134750A (ko) * 2015-04-13 2017-12-06 갈라파고스 엔.브이. 염증 질환의 치료 방법
WO2017106564A1 (fr) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combinaison d'un inhibiteur de jak et d'un inhibiteur de syk pour le traitement de cancers et de troubles inflammatoires
JOP20180018A1 (ar) * 2017-03-14 2019-01-30 Gilead Sciences Inc تركيبات صيدلية تتضمن مثبط jak

Also Published As

Publication number Publication date
GB201808575D0 (en) 2018-07-11
AU2019273664B2 (en) 2025-01-23
JP7751362B2 (ja) 2025-10-08
KR20210013168A (ko) 2021-02-03
EP3801548A1 (fr) 2021-04-14
US20210299135A1 (en) 2021-09-30
WO2019224283A1 (fr) 2019-11-28
CN112203660B (zh) 2024-12-31
AU2025202777A1 (en) 2025-05-08
JP2025183397A (ja) 2025-12-16
US12329758B2 (en) 2025-06-17
CN112203660A (zh) 2021-01-08
AU2019273664A1 (en) 2021-01-21
JP2021524472A (ja) 2021-09-13
JP2024069223A (ja) 2024-05-21
CA3101386A1 (fr) 2019-11-28

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA46954A (fr) Méthodes de traitement d'états inflammatoires
EP3813806A4 (fr) Méthodes de traitement d'un dysfonctionnement mitochondrial
EP3370721A4 (fr) Traitement de l'ostéoarthrite
MA53329A (fr) Méthodes de traitement de l'épilepsie
EP3340971A4 (fr) Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
EP3285776A4 (fr) Méthodes de traitement d'infections bactériennes
EP3625971A4 (fr) Traitement d'audio spatial
EP3775263A4 (fr) Compositions et méthodes de traitement de l'acné
EP3512524A4 (fr) Méthodes et compositions de traitement d'infections virales
EP3503904A4 (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
EP3781653A4 (fr) Traitement de biomasse à ph contrôlé
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
EP3454793A4 (fr) Bobines de traitement d'anévrisme
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3773633A4 (fr) Méthodes de traitement de glioblastomes
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
IL268905B (en) Phage therapy
EP3383857A4 (fr) Composés et méthodes de traitement d'infections bactériennes
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
EP3735209A4 (fr) Traitement de la progression de la myopie
MA46353A (fr) Méthodes de traitement de l'infertilité féminine